File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recombinant α2 interferon is superior to doxorubin for inoperable hepatocellular carcinoma: A prospective randomised trial

TitleRecombinant α2 interferon is superior to doxorubin for inoperable hepatocellular carcinoma: A prospective randomised trial
Authors
Issue Date1989
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjc
Citation
British Journal Of Cancer, 1989, v. 60 n. 6, p. 928-933 How to Cite?
AbstractIn a prospective trial of 75 Chinese patients with histologically proven inoperable hepatocellular carcinoma (HCC), 25 patients were randomised to receive doxorubicin 60-75 mg m-2 intravenously once every 3 weeks, 25 to receive recombinant α2 interferon (rIFN) (Roferon) 9 - 18 x 106 IU m-2 intramuscularly (i.m.) daily and 25 to receive rIFN 25 - 50 x 106 IU m-2 i.m. three times weekly. Patients were switched to the other drug if: (a) there was progressive disease after 12 weeks, (b) unacceptable toxicity developed and (c) they had received a total of 500 mg m-2 of doxorubicin. Six patients had switching over of therapy, three on doxorubicin and three on rIFN. In the remaining 69 patients on single drug therapy, the median survival rate of patients on doxorubicin and rIFN was 4.8 and 8.3 weeks respectively (P = ns). rIFN induced tumour regression of 25-50% in 12% of patients and of over 50% in 10% of patients. When compared with doxorubicin, rIFN was associated with more tumour regression (P = 0.00199) and less progressive tumours (P = 0.00017). It caused less prolonged and less severe marrow suppression (P = 0.01217), and had significantly less fatal complications than doxorubicin (P = 0.01383). Doxorubicin caused fatal complications due to cardiotoxicity and neutropenia in 25% of patients. rIFN was associated with fatal complications due to dementia and renal failure in 3.8% of patients. In the treatment of inoperable HCC, rIFN is superior to doxorubicin in causing more tumour regression, less serious marrow suppression and less fatal complications.
Persistent Identifierhttp://hdl.handle.net/10722/161807
ISSN
2015 Impact Factor: 5.569
2015 SCImago Journal Rankings: 2.939
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLai, CLen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLin, HJen_US
dc.contributor.authorNgan, Hen_US
dc.contributor.authorLau, JYNen_US
dc.contributor.authorChung, HTen_US
dc.contributor.authorNg, MMTen_US
dc.contributor.authorYeoh, EKen_US
dc.contributor.authorArnold, Men_US
dc.date.accessioned2012-09-05T05:15:12Z-
dc.date.available2012-09-05T05:15:12Z-
dc.date.issued1989en_US
dc.identifier.citationBritish Journal Of Cancer, 1989, v. 60 n. 6, p. 928-933en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttp://hdl.handle.net/10722/161807-
dc.description.abstractIn a prospective trial of 75 Chinese patients with histologically proven inoperable hepatocellular carcinoma (HCC), 25 patients were randomised to receive doxorubicin 60-75 mg m-2 intravenously once every 3 weeks, 25 to receive recombinant α2 interferon (rIFN) (Roferon) 9 - 18 x 106 IU m-2 intramuscularly (i.m.) daily and 25 to receive rIFN 25 - 50 x 106 IU m-2 i.m. three times weekly. Patients were switched to the other drug if: (a) there was progressive disease after 12 weeks, (b) unacceptable toxicity developed and (c) they had received a total of 500 mg m-2 of doxorubicin. Six patients had switching over of therapy, three on doxorubicin and three on rIFN. In the remaining 69 patients on single drug therapy, the median survival rate of patients on doxorubicin and rIFN was 4.8 and 8.3 weeks respectively (P = ns). rIFN induced tumour regression of 25-50% in 12% of patients and of over 50% in 10% of patients. When compared with doxorubicin, rIFN was associated with more tumour regression (P = 0.00199) and less progressive tumours (P = 0.00017). It caused less prolonged and less severe marrow suppression (P = 0.01217), and had significantly less fatal complications than doxorubicin (P = 0.01383). Doxorubicin caused fatal complications due to cardiotoxicity and neutropenia in 25% of patients. rIFN was associated with fatal complications due to dementia and renal failure in 3.8% of patients. In the treatment of inoperable HCC, rIFN is superior to doxorubicin in causing more tumour regression, less serious marrow suppression and less fatal complications.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjcen_US
dc.relation.ispartofBritish Journal of Canceren_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma, Hepatocellular - Drug Therapy - Mortalityen_US
dc.subject.meshDoxorubicin - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon Type I - Adverse Effects - Therapeutic Useen_US
dc.subject.meshLeukocyte Count - Drug Effectsen_US
dc.subject.meshLiver Neoplasms - Drug Therapy - Mortalityen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshRecombinant Proteinsen_US
dc.titleRecombinant α2 interferon is superior to doxorubin for inoperable hepatocellular carcinoma: A prospective randomised trialen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/bjc.1989.392-
dc.identifier.pmid2557881-
dc.identifier.scopuseid_2-s2.0-0024805819en_US
dc.identifier.volume60en_US
dc.identifier.issue6en_US
dc.identifier.spage928en_US
dc.identifier.epage933en_US
dc.identifier.isiWOS:A1989CD41400023-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US
dc.identifier.scopusauthoridNgan, H=7102173824en_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridChung, HT=7404007053en_US
dc.identifier.scopusauthoridNg, MMT=7202076310en_US
dc.identifier.scopusauthoridYeoh, EK=35427828500en_US
dc.identifier.scopusauthoridArnold, M=7402910948en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats